SDL in-band pumped Q-switched 2.1 μm Ho:YAG laser

We demonstrate for the first time to our knowledge a Q-switched Ho:YAG laser in-band pumped by a 1.9 μm semiconductor disk laser (SDL). 3.3 mJ of pulse energy were achieved in a compact setup

Long wavelength infrared GaAs/AlGaAs quantum well infrared photodetectors for 630x512 focal plane array camera systems with 20 mK NETD

Photoconductive GaAs/AlGaAs quantum well infrared photodetectors are investigated for the fabrication of IR cameras for thermal imaging in the third atmospheric window. The long wavelength infrared camera consists of a two-dimensional focal-plane array with 640 x 512 detector elements which is flip-chip bonded to a read-out integrated circuit. The technology for the fabrication of the focal-plane arrays, electrical and optical properties of single detector elements in the two-dimensional arrangement and the properties of the camera system are reported. The camera shows excellent spatial resolution with a noise equivalent temperature difference below 20 mK at an operation temperature of T = 60 K

Expert opinion on the use of biological therapy in non-infectious uveitis

cited By 1International audienceIntroduction: Conventional immunosuppressive drugs, anti-TNF alpha treatments and biotherapies are increasingly being used in non-infectious uveitis. Areas covered: The present work was led by a multidisciplinary panel of experts, including internal medicine specialists, rheumatologists and ophthalmologists, and proposes an extensive review on the use of biological agents in non-infectious uveitis. Expert opinion: In case of dependency to steroids or sight-threatening disease, conventional immunosuppressive drugs (methotrexate, azathioprine and mycophenolate mofetil) and/or biological therapies such as anti-TNF alpha treatments (adalimumab, infliximab) can be used to achieve and maintain disease quiescence. Interferon is an efficient immunomodulatory drug that can be proposed as second-line therapy in specific indications (eg. refractory macular edema, sight-threatening Behçet’s uveitis). Other biologics, especially tocilizumab, are showing promising results. Local treatments (steroids, sirolimus etc.) can be used as adjuvant therapies in case of unilateral relapse. Therapeutic response must always be evaluated by clinical examination and appropriate ancillary investigations. © 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group

Therapeutic strategy for the treatment of non-infectious uveitis proposed by an expert panel [Avis d'experts pour le traitement des uvéites non infectieuses]

cited By 1International audienceConventional immunosuppressive drugs, anti-TNF alpha and other biotherapies used in clinical practice are capable of controlling non-infectious anterior uveitis, posterior uveitis and panuveitis. The present work has been led by a multidisciplinary panel of experts, internists, rheumatologists and ophthalmologists and is based on a review of the literature. In case of corticodependency or sight-threatening disease, conventional immunosuppressive drugs (methotrexate, azathioprine and mycophenolate mofetil) and/or anti-TNF alpha (adalimumab, infliximab) are used to achieve and maintain remission. Interferon is an efficient immunomodulatory treatment, as a second-line therapy, for some therapeutic indications (refractory macular edema, Behçet's vascularitis). Other biologics, especially tocilizumab, are showing promising results. Local treatments (corticosteroids, sirolimus etc.) are adjuvant therapies in case of unilateral inflammatory relapse. Therapeutic response must be evaluated precisely by clinical examination and repeated complementary investigations (laser flare photometry, multimodal imaging, perimetry, electroretinography measures). © 2018 Société Nationale Française de Médecine Interne (SNFMI